Kainic acid |
| Catalog No.GC16667 |
Kainic acid (KA), is an analog of the excitotoxic neurotransmitter glutamate. Kainic acid induces seizures.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 487-79-6
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
Kainic acid (KA), is an analog of the excitotoxic neurotransmitter glutamate. Kainic acid induces seizures[1-3].
Kainic acid(200 µM; 45 min) exposure induced caspase and calpain activation in neuronal cultures[4]. Kainic acid(5 µM) induces seizure-like activity in cortical human neurons[5]. Treatments with KA(1-100 µM) resulted in a significant decrease in cell viability in primary cultures of hippocampal neurons [6].
KA-induced(10 mg/kg;i.p) excitotoxicity led to sustained hyperphosphorylation of tau in MAPT transgenic (Tg) mice. This can lead to memory deficits[7]. After 1.0 µg of Kainic acid was injected into the hippocampus of young mice at 6, 7 and 9 days of age, pyramidal cells died significantly [8]. Injection of Kainic acid(70 µl/min; 16 mg/kg;i.v) through the tail vein of a mouse reliably and rapidly induces status epilepticus (SE) which remits spontaneously and leads to the development of temporal lobe epilepsy (TLE) in a subset of mice[9].
References:
[1]. LÉvesque M, Avoli M. The kainic acid model of temporal lobe epilepsy. Neurosci Biobehav Rev. 2013 Dec;37(10 Pt 2):2887-99. doi: 10.1016/j.neubiorev.2013.10.011. Epub 2013 Oct 30. PMID: 24184743; PMCID: PMC4878897.
[2]. Ben-Ari Y, Cossart R. Kainate, a double agent that generates seizures: two decades of progress. Trends Neurosci. 2000 Nov;23(11):580-7. doi: 10.1016/s0166-2236(00)01659-3. PMID: 11074268.
[3]. Barker-Haliski M, White HS. Glutamatergic Mechanisms Associated with Seizures and Epilepsy. Cold Spring Harb Perspect Med. 2015 Jun 22;5(8):a022863. doi: 10.1101/cshperspect.a022863. PMID: 26101204; PMCID: PMC4526718.
[4]. Meade AJ, Meloni BP, et,al. AP-1 inhibitory peptides attenuate in vitro cortical neuronal cell death induced by kainic acid. Brain Res. 2010 Nov 11;1360:8-16. doi: 10.1016/j.brainres.2010.09.007. Epub 2010 Sep 15. PMID: 20833150.
[5]. Mzezewa R, Lotila J, et,al. A kainic acid-induced seizure model in human pluripotent stem cell-derived cortical neurons for studying the role of IL-6 in the functional activity. Stem Cell Res. 2022 Apr;60:102665. doi: 10.1016/j.scr.2022.102665. Epub 2022 Jan 17. PMID: 35091307.
[6]. RodrÍguez-ChÁvez V, Flores-Soto E, et,al. Prolactin reduces the kainic acid-induced increase in intracellular Ca2+ concentration, leading to neuroprotection of hippocampal neurons. Neurosci Lett. 2023 Jul 27;810:137344. doi: 10.1016/j.neulet.2023.137344. Epub 2023 Jun 13. PMID: 37315731.
[7]. Zheng XY, Lv YD, et,al. Kainic acid hyperphosphorylates tau via inflammasome activation in MAPT transgenic mice. Aging (Albany NY). 2019 Dec 2;11(23):10923-10938. doi: 10.18632/aging.102495. Epub 2019 Dec 2. PMID: 31789603; PMCID: PMC6932880.
[8]. Cook TM, Crutcher KA. Intrahippocampal injection of kainic acid produces significant pyramidal cell loss in neonatal rats. Neuroscience. 1986 May;18(1):79-92. doi: 10.1016/0306-4522(86)90180-6. PMID: 3736859.
[9]. Drysdale ND, Matthews E, et,al. Intravenous kainic acid induces status epilepticus and late onset seizures in mice. Epilepsy Res. 2021 Dec;178:106816. doi: 10.1016/j.eplepsyres.2021.106816. Epub 2021 Nov 14. PMID: 34808484; PMCID: PMC8657370.
| Cell experiment [1]: | |
|
Cell lines |
Neuron |
|
Preparation Method |
To induce excitotoxicity in the cortical neuronal cultures 50 µL of conditioned media containing kainic acid was added to culture wells containing 50 µL of conditioned media (200 µM final kainic acid concentration). Cultures were incubated at 37℃ in the CO2 incubator for 45 min for kainic acid, after which time the media was replaced with 100 µL of 50% NB/2% N2 and 50% balance salt solution (NB/N2:BSS). |
|
Reaction Conditions |
200 µM;45 min |
|
Applications |
Acute exposure of neurons to kainic acid induces cell death. |
| Animal experiment [2]: | |
|
Animal models |
C57BL/6 mice |
|
Preparation Method |
Kainic Acid was dissolved in phosphate buffered saline (pH 7.4) at a concentration of one mg/ml and aliquoted, frozen, and stored at 80 ℃. On the day of infusion, an aliquot was removed from the freezer and allowed to come to room temperature prior to infusion; unused excess was discarded. Phosphate buffered saline (PBS) served as vehicle. Five units of heparin were added to every one ml of PBS and one ml of KA. Mice were gently restrained and either KA or PBS solutions infused into lateral tail vein via a 30 gauge needle at an infusion rate of 70 µl/min using a syringe pump. |
|
Dosage form |
70 µl/min; 16 mg/kg;i.v |
|
Applications |
Intravenous infusion of KA reliably induces status epilepticus (SE). |
|
References: [1]. Meade AJ, Meloni BP, et,al. AP-1 inhibitory peptides attenuate in vitro cortical neuronal cell death induced by kainic acid. Brain Res. 2010 Nov 11;1360:8-16. doi: 10.1016/j.brainres.2010.09.007. Epub 2010 Sep 15. PMID: 20833150. | |
| Cas No. | 487-79-6 | SDF | |
| Chemical Name | (2S,3S,4S)-3-(carboxymethyl)-4-(prop-1-en-2-yl)pyrrolidine-2-carboxylic acid | ||
| Canonical SMILES | OC([C@H]1NC[C@H](C(C)=C)[C@@H]1CC(O)=O)=O | ||
| Formula | C10H15NO4 | M.Wt | 213.23 |
| Solubility | ≥ 11.05mg/mL in Water with gentle warming | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 4.6898 mL | 23.4489 mL | 46.8977 mL |
| 5 mM | 0.938 mL | 4.6898 mL | 9.3795 mL |
| 10 mM | 0.469 mL | 2.3449 mL | 4.6898 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 25 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *